An endogenous time-keeping system found in all kingdoms of life, the endogenous circadian clock, is the source of the essential cyclic change mechanism known as the circadian rhythm. The primary circadian clock that synchronizes peripheral circadian clocks to the proper phase is housed in the anterior hypothalamus's suprachiasmatic nuclei (SCN), which functions as a central pacemaker. According to many epidemiological studies, many cancer types, especially brain tumors, have shown evidence of dysregulated clock gene expression, and the connection between clock and brain tumors is highly specific. In some studies, it is reported that the treatment administered in the morning has been linked to prolonged survival for brain cancer patients, and drug sensitivity and gene expression in gliomas follow daily rhythms. These results suggest a relationship between the circadian rhythm and the onset and spread of brain tumors, while further accumulation of research evidence will be needed to establish definitely these positive outcomes as well as to determine the mechanism underlying them. Chronotherapy provides a means of harnessing current medicines to prolong patients' lifespans and improve their quality of life, indicating the significance of circadian rhythm in enhancing the design of future patient care and clinical trials. Moreover, it is implicated that chronobiological therapy target may provide a significant challenge that warrants extensive effort to achieve. This review examines evidence of the relationship of circadian rhythm with glioma molecular pathogenesis and summarizes the mechanisms and drugs implicated in this disease.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ejphar.2024.177144 | DOI Listing |
Transl Cancer Res
December 2024
Department of Radiation Oncology, The Second Hospital of Lanzhou University, Lanzhou, China.
Background: Within the realm of primary brain tumors, specifically glioblastoma (GBM), presents a notable obstacle due to their unfavorable prognosis and differing median survival rates contingent upon tumor grade and subtype. Despite a plethora of research connecting cardiotrophin-1 (CTF1) modifications to a range of illnesses, its correlation with glioma remains uncertain. This study investigated the clinical value of CTF1 in glioma and its potential as a biomarker of the disease.
View Article and Find Full Text PDFHeliyon
July 2024
College of Engineering and IT, University of Dubai, Academic City, 14143, Dubai, United Arab Emirates.
This study proposes a hierarchical automated methodology for detecting brain tumors in Magnetic Resonance Imaging (MRI), focusing on preprocessing images to improve quality and eliminate artifacts or noise. A modified Extreme Learning Machine is then used to diagnose brain tumors that are integrated with the Modified Sailfish optimizer to enhance its performance. The Modified Sailfish optimizer is a metaheuristic algorithm known for efficiently navigating optimization landscapes and enhancing convergence speed.
View Article and Find Full Text PDFTransl Androl Urol
December 2024
Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Background: In renal cell carcinoma (RCC), skin metastases (SMs) occur in only 3.3% of cases and are even rarer as an initial manifestation of the disease. Although combination therapy with immune checkpoint inhibitors (ICIs) and targeted agents is the current standard of care, access to these treatments may be limited in certain regions due to cost constraints.
View Article and Find Full Text PDFCNS Neurosci Ther
January 2025
Department of Neurosurgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Background: Glioblastoma multiforme (GBM) is a common and highly aggressive brain tumor with a poor prognosis. However, the prognostic value of ferroptosis-related genes (FRGs) and their classification remains insufficiently studied.
Objective: This study aims to explore the significance of ferroptosis classification and its risk model in GBM using multi-omics approaches and to evaluate its potential in prognostic assessment.
Acta Neuropathol Commun
January 2025
Department of Neurosurgery, Baylor College of Medicine, Houston, TX, USA.
Glioblastoma is the deadliest primary brain tumor, largely due to inevitable recurrence of the disease after treatment. While most recurrences are local, patients rarely present with a new discontiguous focus of glioblastoma. Little is currently known about the genetic profile of discontiguous recurrences.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!